A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer




TekijätIreland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG, Weyer-Czernilofsky U, Bogenrieder T, Schmid M, Mielgo A

Julkaisuvuosi2018

JournalOncogene

Tietokannassa oleva lehden nimiOncogene

Lehden akronyymiOncogene

Vuosikerta37

Numero15

Aloitussivu2022

Lopetussivu2036

Sivujen määrä15

ISSN0950-9232

eISSN1476-5594

DOIhttps://doi.org/10.1038/s41388-017-0115-x

Verkko-osoitehttps://www.nature.com/articles/s41388-017-0115-x.pdf

Rinnakkaistallenteen osoitehttps://www.nature.com/articles/s41388-017-0115-x.pdf


Tiivistelmä
Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both inhibit and support cancer progression. Thus, gaining a better understanding of how macrophages support cancer could lead to the development of more effective therapies. In this study, we find that breast cancer-associated macrophages express high levels of insulin-like growth factors 1 and 2 (IGFs) and are the main source of IGFs within both primary and metastatic tumors. In total, 75% of breast cancer patients show activation of insulin/IGF-1 receptor signaling and this correlates with increased macrophage infiltration and advanced tumor stage. In patients with invasive breast cancer, activation of Insulin/IGF-1 receptors increased to 87%. Blocking IGF in combination with paclitaxel, a chemotherapeutic agent commonly used to treat breast cancer, showed a significant reduction in tumor cell proliferation and lung metastasis in pre-clinical breast cancer models compared to paclitaxel monotherapy. Our findings provide the rationale for further developing the combination of paclitaxel with IGF blockers for the treatment of invasive breast cancer, and Insulin/IGF1R activation and IGF+ stroma cells as potential biomarker candidates for further evaluation.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 19:24